<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">26093711</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-2623</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Transplantation proceedings</Title><ISOAbbreviation>Transplant Proc</ISOAbbreviation></Journal><ArticleTitle>Analysis of the Humoral Immune Response to Human Leukocyte Antigens in Turkish Renal Transplant Candidates and Relationship Between Autoimmune Disorders.</ArticleTitle><Pagination><StartPage>1326</StartPage><EndPage>1330</EndPage><MedlinePgn>1326-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.transproceed.2015.04.066</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0041-1345(15)00391-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pre-transplant sensitization to human leukocyte antigens (HLA) is a risk factor for graft failure. The purpose of the current single-center study was to evaluate humoral immune response to HLA antigens and the possible relationship between anti-HLA antibody titer and autoimmune disorders in renal transplant candidates.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 435 renal transplant candidates were analyzed; 50 sensitized patients were enrolled in this study. The HLA typing was performed by use of enzyme-linked immunoassay combined with Luminex technology. The patients were questioned for clinical evidence of hypothyroidism and systemic lupus erythematosus (SLE) and investigated for anti-nuclear antibody (ANA), anti-double-stranded DNA (anti-dsDNA), anti-thyroglobulin (anti-TG), anti-thyroid peroxidase (anti-TPO) antibodies, and thyroid function tests.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 50 patients with positive panel reactive antibody, 24 (48%) were positive for class I and negative for class II, 12 (24%) were negative for class I and positive for class II, and 14 (28%) were positive for both classes I and II. The specificities of anti-HLA antibodies-A23, A68, A69, B27, B49, DR6, and DR8-were the most frequent. ANA and anti-dsDNA antibodies were not correlated with either clinical symptoms of SLE or anti-HLA antibody titer of renal transplant candidates. Similarly, anti-TG and anti-TPO antibodies were not correlated with clinical hypothyroidism or anti-HLA antibody titer.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data have demonstrated the profile of anti-HLA antibodies in patients who were on the renal transplant waiting list in Turkey. The most frequent specificities of anti-HLA antibodies were A23, A68, A69, B27, B49, DR6, and DR8. There was no association between anti-HLA antibody titer and clinical and laboratory evidence of SLE and hypothyroidism.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ari</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Kartal Research and Training Hospital, Istanbul, Turkey. Electronic address: elifaribakir@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yildirim</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Transplantation, Kartal Research and Training Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kucuk</LastName><ForeName>H F</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Department of Transplantation, Kartal Research and Training Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durmaz</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Transplantation, Kartal Research and Training Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dogu</LastName><ForeName>Z</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Transplantation, Kartal Research and Training Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yavuz</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Kartal Research and Training Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parmaksiz</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Kartal Research and Training Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asicioglu</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Kartal Research and Training Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carin</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology, Bilim University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transplant Proc</MedlineTA><NlmUniqueID>0243532</NlmUniqueID><ISSNLinking>0041-1345</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000949">Histocompatibility Antigens Class II</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C006606">anti-thyroglobulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000949" MajorTopicYN="N">Histocompatibility Antigens Class II</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007037" MajorTopicYN="N">Hypothyroidism</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="Y">Kidney Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014421" MajorTopicYN="N">Turkey</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26093711</ArticleId><ArticleId IdType="doi">10.1016/j.transproceed.2015.04.066</ArticleId><ArticleId IdType="pii">S0041-1345(15)00391-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>